|
Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Millennium (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - 3D Biopsy; Abbvie; Gilead Sciences; Lightspeed microscopy; Protean Biodiagnostics |
Research Funding - Intuitive Surgical (Inst) |
|
|
Stock and Other Ownership Interests - Artera |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol Myers Squibb; Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; Roivant; SerImmune; Varian Medical Systems |
Research Funding - Zenith Epigenetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Boston Scientific; Merck; Myovant Sciences; Roivant |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Radiogel |
Consulting or Advisory Role - Janssen |
Other Relationship - Caribou Publishing |